Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $438.7 million.

  • Monte Rosa Therapeutics' Liabilities and Shareholders Equity rose 45.94% to $459.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 34.29%. This contributed to the annual value of $438.7 million for FY2024, which is 44.44% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Liabilities and Shareholders Equity is $438.7 million, which was up 44.44% from $303.8 million recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Liabilities and Shareholders Equity peaked at $438.7 million during FY2024, and registered a low of $303.8 million during FY2023.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $371.2 million (2023), whereas its average is $371.2 million.
  • Data for Monte Rosa Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 44.44% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $303.8 million in 2023, then spiked by 44.44% to $438.7 million in 2024.